PUBLISHER: Azoth Analytics | PRODUCT CODE: 1082038
PUBLISHER: Azoth Analytics | PRODUCT CODE: 1082038
According to Azoth Analytics research report, the Global Rare Disease Drugs was valued at USD 147.12 Billion in the year 2021. The increasing focus on research activities and the development of novel therapeutic drugs has facilitated the growth of the Rare Disease Drugs market. Additionally, growing product developments is leading to the implementation of technologically driven innovative devices in the diagnosis of rare genetic disorders.
Moreover, favourable government policies aiming at creating awareness pertaining to the Rare Disease treatment are leading to increased adoption of effective treatments of rare disorders. However, there are several factors hindering the efficient and effective clinical trials of drug development of rare disorders including low patient numbers, limited understanding of pathology and progression, and lack of established endpoints. Therefore, several regulatory bodies are engaged in implementing regulatory standards for drug approval for Rare diseases to ensure patient safety and efficacy of drugs.
Furthermore, improved detection and increased rates of diagnosis of Rare diseases are likely to contribute to rising costs. While the humanitarian benefits of Rare Disease therapies are indisputable, concerns regarding high treatment costs play a meaningful role in how payers administer and manage healthcare benefits that ultimately dictate patient access to orphan drugs. Moreover, the biological drugs are used for treating Rare diseases such as cancer with fewer side effects that have a high prevalence rate in the developed world.
5.1 Competitive Scenario of Global Rare Disease Drugs Market: By Drug Type